A5078289071- Coronary Interventions and Diagnostics
- Peripheral Artery Disease Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Valve Diseases and Treatments
- Cardiac Imaging and Diagnostics
- Private Equity and Venture Capital
- Cardiac Structural Anomalies and Repair
- Metal and Thin Film Mechanics
- Cardiac pacing and defibrillation studies
- Pain Management and Treatment
- Coronary Artery Anomalies
- Kawasaki Disease and Coronary Complications
- Magnesium Alloys: Properties and Applications
- Acute Myocardial Infarction Research
Azienda Socio Sanitaria Territoriale Bergamo Est
2017-2020
Azienda Ospedaliera Bolognini Seriate
2016-2018
To date, very little is known about the performance of a sirolimus-eluting bioresorbable magnesium scaffold (Mg-BRS) in patients with acute myocardial infarction (AMI). A multicenter cohort analysis was performed on 69 consecutive AMI subjects treated Mg-BRS. Procedural success obtained all cases, and no in-hospital events were reported. At 9-month follow-up, cardiac death, target-vessel infarction, ischemia-driven target lesion revascularization, or Mg-BRS thrombosis Although our showed...
to compare the 1-year outcome between bioresorbable vascular scaffold (BVS), everolimus-eluting stent (EES), and drug-eluting balloon (DEB) for in-stent restenosis (ISR) treatment.BVS has been proposed as alternative ISR treatment. To date a direct comparison BVS DES or DEB treatment is lacking.We retrospectively analyzed all lesions treated with BVS, DEB, EES from January 2012 December 2014. A total of 548 (498 patients) were included. By applying two propensity-score matching, 93 compared...
A large trial established the favourable clinical profile of a new polymer-free biolimus A9-eluting stent (PF-BES) with one-month dual antiplatelet therapy (DAPT) regimen in patients at high bleeding risk (HBR). We aimed to evaluate real-world patterns indications, DAPT strategies and outcomes for PF-BES following this evidence.CHANCE is multicentre registry including all who underwent percutaneous coronary intervention (PCI) least one PF-BES. The reasons PCI planned antithrombotic regimens...
A large trial established the favorable profile of a new polymer-free biolimus A9-eluting stent (PF-BES) with 1-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients. This is first study comparing outcomes for versus longer DAPT strategies following PF-BES-percutaneous coronary intervention (PCI).All patients undergoing PF-BES-PCI (January 2016 to July 2018) were included multicenter CHANCE registry. Patients stratified according strategy at discharge (planned vs....